Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.45 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.45 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.45 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.42 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.40 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29242576 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRPOLBL3MBTL1 | |
| SCHEMBL69460 | 0.97 | ALDH1A1 (0.56) | ALDH1A1TDP1TSHRPOLBL3MBTL1 | |
| SCHEMBL29492110 | 0.97 | ALDH1A1 (0.56) | ALDH1A1TDP1TSHRPOLBL3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL28699487 | 0.95 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRPOLBL3MBTL1 | |
| SCHEMBL11348739 | 0.95 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRPOLBL3MBTL1 | |
| Potassium SCHEMBL29898272 | 0.95 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRPOLBL3MBTL1 | |
| Bromide SCHEMBL1854329 | 0.95 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRPOLBL3MBTL1 | |
| SCHEMBL28955073 | 0.95 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRPOLBL3MBTL1 | |
| SCHEMBL27510755 | 0.95 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRPOLBL3MBTL1 | |
| Trimethylammonium SCHEMBL23035406 | 0.88 | TDP1 (0.54) | ALDH1A1TDP1TSHRPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658649-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINES AND [1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS NLRP3 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-11-12 | — | — | US | disclosed |
| WO-2024160694-A1 | [1,2,4]TRIAZOLO[4,3-a]PYRIDINES AND [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS NLRP3 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-08 | — | — | WO | disclosed |
| WO-2023088856-A1 | HETEROCYCLIC NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |
| US-11638706-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11608501-B2 | Methods for modifying RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20220387428-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2022-08-11 | — | — | US | disclosed |
| US-11229648-B2 | 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2022-01-25 | — | — | US | disclosed |
| US-20200370043-A1 | METHODS FOR MODIFYING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200345732-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-11-05 | — | — | US | disclosed |
| EP-3638318-A1 | METHODS FOR MODIFYING RNA SPLICING | PTC Therapeutics, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20200113904-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2020-04-16 | — | — | US | disclosed |
| US-10195196-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2019-02-05 | — | — | US | disclosed |
| US-20190000844-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2019-01-03 | — | — | US | disclosed |
| WO-2018232039-A1 | METHODS FOR MODIFYING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| EP-3386511-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20170290828-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2017-10-12 | — | — | US | disclosed |
| WO-2017100726-A1 | METHODS FOR TREATNG HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000844-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | CA2 2533/4885EGFR 3149/4885PIK3CA 3703/4885 |
| US-20200370043-A1 | METHODS FOR MODIFYING RNA SPLICING | RBM17, SNRPE, SNRPA1 | CA2 4884/4885EGFR 4507/4885PIK3CA 4608/4885 |
| US-20200113904-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | CA2 2533/4885EGFR 3149/4885PIK3CA 3703/4885 |
| US-11229648-B2 | 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, SF3B5, CLN6 | CA2 3716/4885EGFR 4690/4885PIK3CA 1156/4885 |
| US-20170290828-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | CA2 3645/4885EGFR 4644/4885PIK3CA 1320/4885 |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | CA2 4017/4885EGFR 4602/4885PIK3CA 2859/4885 |
| US-20200345732-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | CA2 3645/4885EGFR 4644/4885PIK3CA 1320/4885 |
| US-11608501-B2 | Methods for modifying RNA splicing | RBM17, SNRPA1, SNRPE | CA2 4882/4885EGFR 4727/4885PIK3CA 4547/4885 |
| US-20220387428-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | CA2 3645/4885EGFR 4644/4885PIK3CA 1320/4885 |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | CA2 4017/4885EGFR 4602/4885PIK3CA 2859/4885 |
| US-10195196-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, CLN6, SF3B5 | CA2 3645/4885EGFR 4644/4885PIK3CA 1320/4885 |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | CA2 4017/4885EGFR 4602/4885PIK3CA 2859/4885 |
| US-11638706-B2 | Methods for treating Huntington's disease | HTT, HYPK, FH | CA2 2533/4885EGFR 3149/4885PIK3CA 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.